AbbVie

Open: 151.07 Close: 149.25 Change: -1.82

Don't invest in AbbVie before reading this automated analysis produce by an AI.

This document will help you to evaluate AbbVie without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, company, Inc, revenue, Abbvie, link, report, and the …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie Inc. reports 9.7% fall in global net revenues for q1 2022. The company trimmed its full-year profit expectations earlier this month by 8 cents citing a $150 million hit from acquired in-process research and development expenses. The Yes link below will take you out of the family of websites.

Today's News

AbbVie Inc. reports 9.7% fall in global net revenues for q1 2022. Abbvie has reported global net revenue of $12.23bn for first quarter (Q1) of 2023, representing a decline of 9. 7% on a reported basis and 8.3% on an operational basis. AbbVie dropped almost 8% after its most recent earnings release. Lower-than-expected guidance and a sales decline caused by the Humira patent loss. AbbVie beat sales expectations with revenue of $12.23 billion, topping estimates. The company trimmed its full-year profit expectations earlier this month by 8 cents citing a $150 million hit from acquired in-process research and development expenses. AbbVie Inc. came out with quarterly earnings of $2.46 per share, beating the Zacks Consensus Estimate. Skyrizi risankizumab-rzaa that fell short of analysts consensus. AbbVie Inc. (ABBV) has been one of the stocks most watched by Zacks.com users lately. The company will announce its first-quarter 2023 financial results on April 27, 2023. AbbVie Inc. Stock underperforms Wednesday when Compared To Competitors. Vertex Pharmaceuticals Stock Is an Even Better Buy Now Thanks to Abbvie. AbbVie announced positive top-line results from INSPIRE, a Phase 3 induction study, showing Skyrizi (risankizumabous) met the primary endpoint of clinical remission at all secondary endpoints in adult patients with moderately to severely active Crohns disease (CD) AbbVie is raising its adjusted diluted EPS guidance for the full year 2023 from $10.62 - $11.02 to $10.72 -  $11.12. The CRL did not request that Abbvie conduct additional efficacy and safety trials. The AbbVie Press Kit is designed to provide journalists with a broad range of background information on our company. Humira revenue “is tracking as expected, with much of the impact driven by price” AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The Yes link below will take you out of the family of websites. AbbVie to present at the Bank of America Securities Healthcare Conference on May 9, 2023. The company announced positive data from its Phase 3 ELEVATE study, evaluating atogepant for the preventive treatment of episodic migraine. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by Abbvie. View our social media channel guidelines. AbbVie employees share photos with their families and discuss how they recognize Eid al-Fitr. Join us tomorrow morning at 8am CT as we share our Q1 2023 #FinancialResults.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

How much time have you spent trying to decide whether investing in AbbVie? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, company, Inc, revenue, Abbvie, link, report, and the most common words in the summary are: abbvie, stock, news, market, new, inc, report, . One of the sentences in the summary was: The company trimmed its full-year profit expectations earlier this month by 8 cents citing a $150 million hit from acquired in-process research and development expenses. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #news #market #new #inc #report.